Leanne Larson, global head of observational research at clinical research organization PAREXEL International, explains the expanded knowledge base that electronic health records data can bring to the drug development and market access processes:

Bringing a biopharmaceutical product to market in today’s rapidly evolving healthcare system is a complex process.  In addition to the purely scientific challenge of developing new and innovative treatments for diseases of great complexity, gaining broad market access for these products demands answers far beyond those offered by traditional clinical trial data.  Yet broad market and patient access is the ultimate goal – the only way to truly realize the promise offered by these new and often ground-breaking therapies.  

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access